An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Lisdexamfetamine Dimesylate capsules 70 mg, manufactured by Sun Pharmaceutical Industries Limited, India with VENVANSE (lisdexamfetamine dimesylate) 70 mg Hard Gelatin Capsule, imported and registered by: Takeda Pharma Ltd. Rodovia SP 340 S/N, km 133.5, Ed. Adm. Jaguariúna-SP CNPJ 60.397.775/0001-74 and manufactured by: Patheon Pharmaceuticals Inc. Cincinnati, United States of America or Takeda Pharma Ltd. Rodovia SP 340 S/N, km 133.5, Ed. QC - Jaguariúna – SP, Brazilian industry in healthy adult, human subjects under fasting condition.

2025-521224-29-00 Protocol LISDE-01-25 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 20 Feb 2026 · End 24 Mar 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol LISDE-01-25

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 54
Countries 1
Sites 1

ADHD (Attention Deficit Hyperactivity Disorder)

Key facts

Sponsor
Sun Pharmaceutical Industries Limited
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Psychiatry and Psychology [F] - Mental Disorders [F03]
Trial duration
20 Feb 2026 → 24 Mar 2026
Decision date (initial)
2025-06-30
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

ADHD (Attention Deficit Hyperactivity Disorder)

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sun Pharmaceutical Industries Limited

Sponsor organisation
Sun Pharmaceutical Industries Limited
Address
1 Plot No 201 B, Western Express Highway, Goregaon East Western Express Highway Goregaon East
City
Mumbai
Postcode
400063
Country
India

Scientific contact point

Organisation
Sun Pharmaceutical Industries Limited
Contact name
Arshad Khuroo

Public contact point

Organisation
Sun Pharmaceutical Industries Limited
Contact name
Arshad Khuroo

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Romania Ended 54 1
Rest of world 0

Investigational sites

Romania

1 site · Ended
Terapia S.A.
Clinical Pharmacology and Pharmacokinetics, Strada Fabricii Nr. 124, 400640, Cluj-Napoca

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Romania 2026-02-20 2026-03-24 2026-02-25 2026-03-03

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-08 Romania No conclusion
2025-06-23
2025-06-30